Recordati SpA (FRA:RER1) Tax Provision : €-120 Mil (TTM As of Sep. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Recordati SpA Tax Provision?

Recordati SpA's tax provision for the three months ended in Sep. 2024 was €-37 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2024 was €-120 Mil.

Recordati SpA Tax Provision Historical Data

The historical data trend for Recordati SpA's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recordati SpA Tax Provision Chart

Recordati SpA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

-75.28

-100.63

-77.38

-89.10

-101.82

Recordati SpA Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Tax Provision	Get a 7-Day Free Trial															-23.91	-16.62	-37.55	-28.82	-37.00

Recordati SpA Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-120 Mil.

Recordati SpA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Recordati SpA (FRA:RER1) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

RICFY:USA REC:Italy RECm:UK 0KBS:UK RER1:Germany REC:Austria

Address

Via Matteo Civitali 1, MIlan, ITA, 20148

Website

https://www.recordati.com

Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment which includes the production of active ingredients.

Recordati SpA Headlines

No Headlines